Clinical and biological implications of driver mutations in myelodysplastic syndromes. - Test2 - elhamkhani - TriplyDB

Clinical and biological implications of driver mutations in myelodysplastic syndromes.

Clinical and biological implications of driver mutations in myelodysplastic syndromes.

http://www.wikidata.org/entity/Q37334716

about

Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2 Aging of hematopoietic stem cells: DNA damage and mutations?A clinical-molecular update on azanucleoside-based therapy for the treatment of hematologic cancers Spliceosomal gene mutations in myelodysplasia: molecular links to clonal abnormalities of hematopoiesis Epigenetic modulators, modifiers and mediators in cancer aetiology and progression Cytogenetic and molecular abnormalities in chronic myelomonocytic leukemia Molecular landscape of acute myeloid leukemia in younger adults and its clinical relevance Functions of TET Proteins in Hematopoietic Transformation Intra-tumor heterogeneity of cancer cells and its implications for cancer treatment Myelodysplastic syndromes: 2015 Update on diagnosis, risk-stratification and management Molecular Testing in Myelodysplastic Syndromes for the Practicing Oncologist: Will the Progress Fulfill the Promise?Deciphering intratumor heterogeneity and temporal acquisition of driver events to refine precision medicine Revisiting the case for genetically engineered mouse models in human myelodysplastic syndrome research Connections between TET proteins and aberrant DNA modification in cancer Cancer evolution: mathematical models and computational inference Next-generation sequencing of acute myeloid leukemia identifies the significance of TP53, U2AF1, ASXL1, and TET2 mutations RUNX1 mutations in acute myeloid leukemia are associated with distinct clinico-pathologic and genetic features.Genomic Classification and Prognosis in Acute Myeloid Leukemia.DNMT3A and TET2 in the Pre-Leukemic Phase of Hematopoietic Disorders Emerging concepts of epigenetic dysregulation in hematological malignancies MDS prognostic scoring systems – past, present, and future Oral Azacitidine (CC-486) for the Treatment of Myelodysplastic Syndromes and Acute Myeloid Leukemia Inactivating CUX1 mutations promote tumorigenesis Leukemia-associated somatic mutations drive distinct patterns of age-related clonal hemopoiesis Age-related clonal hematopoiesis associated with adverse outcomes Myelodysplastic Syndromes Diagnosis: What Is the Role of Molecular Testing?Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes MDS-associated somatic mutations and clonal hematopoiesis are common in idiopathic cytopenias of undetermined significance Development of synchronous VHL syndrome tumors reveals contingencies and constraints to tumor evolution The European Hematology Association Roadmap for European Hematology Research: a consensus document Management of lower-risk myelodysplastic syndromes without del5q: current approach and future trends.Established and emerging targeted therapies in the myelodysplastic syndromes.Recent advances in the understanding of myelodysplastic syndromes with ring sideroblasts.Mutational landscapes of tongue carcinoma reveal recurrent mutations in genes of therapeutic and prognostic relevance.Functionally identifiable apoptosis-insensitive subpopulations determine chemoresistance in acute myeloid leukemia.Deciphering clonality in aneuploid breast tumors using SNP array and sequencing data.Combining gene mutation with gene expression data improves outcome prediction in myelodysplastic syndromes.Identification of expression patterns in the progression of disease stages by integration of transcriptomic data.Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis [Myelodysplastic syndromes].

P2860

Q24568313-A1148D53-4019-4F1B-BD09-C61D6739302F Q26741217-4D96C354-FB9C-40EC-804B-5E564F6A7909 Q26743743-F406CA3E-C098-40A6-811E-E006FBA991E9 Q26752221-329DDAD7-A771-4966-AD25-92426DC756D1 Q26766149-0FF30E92-6045-4E9A-A04C-651C8A12119A Q26768600-DA092DA4-E0C0-4896-B936-3C5DA382F435 Q26776393-4EE55C2C-2DC2-4EB4-8801-EC9AF635FCD4 Q26778323-6883F56F-9843-4347-9BCD-9A88A7C2E582 Q26783055-F7DCEE11-DE00-49D2-A6F1-30D4666A732B Q26796240-2F1E7F7B-179C-4DBC-8A4D-F1C1912AAE9F Q26801573-ECE132F3-C71E-4508-8347-28A0ECFBB4EF Q26825186-C08CFC29-09B9-4BDB-88F8-EC99CFE77F0E Q26859843-76DC875D-B56F-4B33-A140-0CB5FD469251 Q26865671-90530D6C-76DE-4BCC-840C-7AED024003C4 Q27002537-D1620CB6-AE9C-46C1-B53A-B0F1BB5160FF Q27853094-9EFCABE1-E9E0-4E4E-96A0-0C8E431F03D0 Q27853381-8D489E95-59C6-42E3-A04F-43EF1EB59CFC Q27853389-5D8F63A8-2AB6-4377-BCAA-3F4A1B729143 Q28073970-88B74D63-8F89-4BED-9CF8-632094BF243F Q28074522-9ED468D6-0471-46F7-B5C8-01E3E60B6657 Q28082460-C69534E5-0A6D-424B-B32B-944BE9E0E337 Q28084813-09441E7F-8606-4AA3-A257-D5592875151E Q28303563-4425773D-5481-4EEB-BF5B-6C8490C8B308 Q28386212-1654AA5B-9B5A-40AE-80AC-27AF9ABE2907 Q28386602-6317CF42-0060-4DDA-BD94-9C11A80FFADE Q28387115-B1DEB1DD-10A4-426D-A7E5-1836AA6BEFD3 Q28392451-DF496647-BF10-4C35-BE56-5B32387DCC12 Q28394317-1A0FD49C-D20B-4F8F-9F3D-6B277C8D155D Q28655705-44865923-6A41-40CD-99C4-99DD52A2F80C Q28830861-FA60FDB2-7F65-4E63-B704-971540CDE4F4 Q30235355-A6CCA814-917F-483F-BC38-269D149F7AA7 Q30245476-BF456C72-A599-4271-9AE1-6946DD6FD4FC Q30249108-5A7A4F78-B473-48B0-BEE1-EE84F1828AAF Q30665308-044F7A39-EE0A-4509-ABA8-647F67294847 Q30827619-A6DD8E80-D27C-45C1-98AC-728B0907FA56 Q30856576-049AE8CF-20B2-492B-9F44-A66AEBF4EE4E Q30883788-FF66EE36-C75B-4497-BF6D-C19826193F17 Q31160928-14E071C3-5E48-410C-BA81-05B1FA50EC78 Q33416223-B8FCB960-F18E-4D68-BBED-C2D00F6B88E6 Q33420574-39B58BCC-8BD1-4EDF-BE10-0B68AC91C59A

P2860

Clinical and biological implications of driver mutations in myelodysplastic syndromes.

http://www.wikidata.org/entity/Q37334716

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 12 September 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Clinical and biological implications of driver mutations in myelodysplastic syndromes.

@en

Clinical and biological implications of driver mutations in myelodysplastic syndromes.

@nl

type

label

Clinical and biological implications of driver mutations in myelodysplastic syndromes.

@en

Clinical and biological implications of driver mutations in myelodysplastic syndromes.

@nl

prefLabel

Clinical and biological implications of driver mutations in myelodysplastic syndromes.

@en

Clinical and biological implications of driver mutations in myelodysplastic syndromes.

@nl

P1433

Q37334716-EB6ED5BE-3C6E-44D6-9F7D-F506278057C5

P1476

Q37334716-D0F10712-5B3B-444C-B3F4-9FE90805881E

P2093

Q37334716-041A691D-E4F6-4888-BE15-6369B0EE513D

Q37334716-0BFBC9C5-1A09-4FF1-9EF8-1FCF25A0E3C4

Q37334716-38433AA5-6E31-4864-99B0-3360B1B034D5

Q37334716-39957142-767B-4528-8C1D-537FCA107B18

Q37334716-5321B640-65FC-48FC-B217-9AF46D8C5253

Q37334716-5FC2E7A2-3726-40FE-8CC7-13A1BC4842B9

Q37334716-69D7F28A-2AA9-441B-96B0-259414F3DB8E

Q37334716-75D0C130-65D5-45A8-AC02-781DA997544F

Q37334716-78DD3DF0-BE3B-4985-9D33-0BE1E98313DA

Q37334716-7DB8AEF4-8737-4391-85B6-411DE140F65E

P2860

Q37334716-00B37206-72AD-466C-8277-0C097BB24AB2

Q37334716-0A4BAB30-BFB0-46C0-A652-08208AB7D745

Q37334716-0DE76A68-23C5-4F7F-9A32-41CA69DCEE68

Q37334716-1616D74F-FA97-453E-8A22-5404E0CB47CE

Q37334716-2A2CE63C-CB9D-489F-A9A3-683D94D22556

Q37334716-2FE0792E-BD67-4E67-A97F-B5713828891F

Q37334716-33DA31D3-C0DA-4E82-B95C-F964C21BCE9B

Q37334716-3AEE5142-0733-4366-A6F5-3F7FB2C9806D

Q37334716-4692E6CB-F3B8-408F-97E1-8B966DB62176

Q37334716-4B2E01DE-6543-4344-900C-28BFFBBACC00

P304

Q37334716-942020B2-D740-4933-B307-54AECE30D520

P31

Q37334716-46EEC6A5-ED6C-4445-8D2E-1A27249AF963

P356

Q37334716-F8CA7BB3-975A-4690-8419-B97A7B31DCBD

P407

Q37334716-FC4EE26F-F36F-4F4D-8334-49E717BEF60A

P433

Q37334716-0D408DFE-030A-4F84-92D9-3813124C310C

P478

Q37334716-EDBB1071-3388-4FB3-8F3D-B8BB6D775C98

P50

Q37334716-0BD05621-2487-4476-8920-D57AF0764B96

Q37334716-162E75E4-E722-44AD-A9D8-9F94F308F69C

Q37334716-29516998-E8F1-40F9-B214-7CB88F4E9C33

Q37334716-301B19D9-080D-4AB9-965F-5469A51AD71F

Q37334716-37844394-F2B9-4F25-9F49-B22FA0C5D9D9

Q37334716-37EB7E13-E69E-4FFE-B563-ABB10B01B85C

Q37334716-53DAEB6A-D936-4A10-872F-2EB3040BBC56

Q37334716-6F22DBB8-63F1-4C16-B099-18C38B04C91F

Q37334716-7C1AD736-1347-4D5D-9370-6399D7DAFA7D

Q37334716-866CD45B-8C77-48FA-B60B-8BAF52B2995D

P577

Q37334716-64FF9D81-B4EF-48A1-8C25-246F5116E9E4

P5875

Q37334716-D290BCBB-D176-4430-B58F-54F153493B05

P698

Q37334716-236F8A1D-E92D-403F-BA7E-E551FE7B8068

P932

Q37334716-0C34AF07-D4A1-4A53-B74D-1D1206CC9656

P356

BLOOD-2013-08-518886

P1433

P1476

Clinical and biological implications of driver mutations in myelodysplastic syndromes.

@en

P2093

Adam P Butler

http://www.w3.org/2001/XMLSchema#string

Adam Shlien

http://www.w3.org/2001/XMLSchema#string

Alex Sternberg

http://www.w3.org/2001/XMLSchema#string

Anna Galli

http://www.w3.org/2001/XMLSchema#string

Chris J Yoon

http://www.w3.org/2001/XMLSchema#string

Chronic Myeloid Disorders Working Group of the International Cancer Genome Consortium

http://www.w3.org/2001/XMLSchema#string

Claire Hardy

http://www.w3.org/2001/XMLSchema#string

David Bowen

http://www.w3.org/2001/XMLSchema#string

Eva Hellstrom-Lindberg

http://www.w3.org/2001/XMLSchema#string

Gunes Gundem

http://www.w3.org/2001/XMLSchema#string

P2860

Cancer genome landscapes

The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes

ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression

COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer

Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms

The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia

Recurrent DNMT3A mutations in patients with myelodysplastic syndromes

Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts

Recurrent SETBP1 mutations in atypical chronic myeloid leukemia

Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing

P304

3616-27; quiz 3699

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2013-08-518886

http://www.w3.org/2001/XMLSchema#string

P407

P433

22

http://www.w3.org/2001/XMLSchema#string

P478

122

http://www.w3.org/2001/XMLSchema#string

P50

Carlo Gambacorti-Passerini

Andrea Pellagatti

Jacqueline Boultwood

Eva Hellström-Lindberg

Elli Papaemmanuil

P577

2013-09-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

256541005

http://www.w3.org/2001/XMLSchema#string

P698

24030381

http://www.w3.org/2001/XMLSchema#string

P932

3837510

http://www.w3.org/2001/XMLSchema#string